Poitiers

• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer … Recruiting
  2024-512279-10-00 5 2024-11-25 Triple Negative Breast Cancer
• Short versus long antiplatelet therapy after TAVI Recruiting
  2023-508208-40-00 10 2024-11-21 All adult patients with successful transfemoral trans-aortic valve imp
• HR-NBL2: High-risk neuroblastoma study 2.0 of SIOP-Europe- Neuroblastoma/SIOPEN: Randomised, international and multicentric phase 3 study t … Recruiting
  2024-514917-36-00 5 2024-11-21 Patients with High Risk Neuroblastoma
• Randomized Phase II, 2-arm Study of Immunomodulation with Atezolizumab concomitant with High Dose Radiation (SBRT) Versus SBRT Alone in Pati … Recruiting
  2024-511313-38-00 4 2024-11-17 Soft Tissue Sarcoma
• Hypertension induced by intravenous administration of norepinephrine to improve the prognosis of patients with neurological deterioration in … Recruiting
  2023-508704-37-00 5 2024-11-08 Stroke
• A proof-of-concept study to learn whether linvoseltamab can eliminate abnormal plasma cells that may lead to multiple myeloma in adult patie … Recruiting
  2023-505242-25-00 4 2024-11-05 High-Risk Monoclonal Gammopathy of Undetermined Significance; Non-Hig
• A phase 3 trial comparing a therapeutic cancer vaccine OSE2101 to chemotherapy docetaxel in patients with metastatic Non-Small Cell Lung Can … Recruiting
  2023-509340-10-00 5 2024-10-29 Patients with HLA-A2 positive phenotype and metastatic Non-Small Cell
• Beamion PANTUMOR-1: A study to test whether zongertinib helps people with advanced cancers with HER2 alterations Recruiting
  2023-510429-14-00 4 2024-10-22 HER2-mutated or overexpressed/amplified solid tumours
• Comparison of Two Antibiotic Regimens for the Treatment of Early Airways Infection With PA in Adults With Bronchiectasis Recruiting
  2023-504755-26-00 4 2024-10-21 Bronchiectasis
• Reduction in the number of chemotherapy cycles in combination with Pembrolizumab in first-line treatment of PD-L1-positive recurrent or meta … Recruiting
  2024-514875-16-00 4 2024-10-21 First-line treatment of PD-L1-positive recurrent or metastatic head an
• FIRST LINE CHEMOTHERAPY FOR METASTATIC GASTRO ENTERO PANCREATIC NEUROENDOCRINE CARCINOMA Recruiting
  2024-515300-39-00 4 2024-10-18 METASTATIC GRADE 3 POORLY DIFFERENTIATED NEUROENDOCRINE CARCINOMA OF G
• Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis Recruiting
  2023-504724-25-00 5 2024-10-16 Primary Myelofibrosis
• An international multicentric randomized phase II evaluating dostarlimab in combination with niraparib versus niraparib alone compared to ch … Recruiting
  2024-516782-36-00 4 2024-10-15 metastatic or recurrent endometrial or ovarian carcinosarcoma
• Treatment with darolutamide +/- radiation therapy for patients with a castration resistant cancer and metastases detected by functional imag … Recruiting
  2023-507482-26-00 5 2024-10-04 Castrate-resistant prostate cancer with oligometastases on functional
• ARGO Colchicine versus Placebo in Acute Myocarditis Patients to Reduce Late Gadolinium Enhancement Mass on Cardiac Magnetic Resonance and th … Recruiting
  2024-514610-13-00 5 2024-10-04 patients suffering from acute myocarditis confirmed on Cardiac magneti
• Linezolid or vancomycin surgical site infection prophylaxis LOVip Recruiting
  2023-504986-22-00 5 2024-09-30 surgical antibiotic prophylaxis
• tislelizUMaB in canceR patients with molEcuLar residuaL disease (UMBRELLA) Recruiting
  2023-503316-33-00 5 2024-09-26 patients with a positive status for molecular residual disease (MRD) [
• PRODIGE 98- AMPIRINOX : Randomized, multicenter, Phase III trial of adjuvant chemotherapy with modified FOLFIRINOX versus capecitabine or ge … Recruiting
  2024-511070-68-01 5 2024-09-24 Ampullary adenocarcinoma
• A Window of Opportunity Trial To Learn If Linvoseltamab Is Safe And Well Tolerated, And How Well It Works In adult Participants With Recentl … Recruiting
  2022-500800-24-00 4 2024-09-19 Multiple Myeloma
• Prospective study in patients with colon or rectum cancer with liver metastasis of the efficacy and toxicity of standard therapy (chemothera … Recruiting
  2024-517204-11-00 4 2024-08-30 microsatellite stable (MSS) colorectal cancer with liver-dominant meta
• PRODIGE 70 - CIRCULATE - CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II Recruiting
  2024-515297-27-00 5 2024-08-14 colon carcinoma
• PRODIG : Prevention of new onset diabetes after transplantation by a short term treatment of Vildagliptin in the early post-transplant perio … Recruiting
  2024-516272-14-00 5 2024-08-13 renal transplant
• A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Lisaftoclax (APG-2575) in Previously Treated Patients with Chro … Recruiting
  2023-508005-24-00 5 2024-08-01 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
• Ezabenlimab (BI 754091) and DCFm (docetaxel, cisplatin and 5-fluorouracil) followed by chemoradiotherapy for the treatment of stage III anal … Recruiting
  2024-514083-31-00 4 2024-07-26 squamous cell anal carcinoma

Showing 217–240 of 615 trials